Ar aberrations and resistance to abiraterone or enzalutamide

Resistance to abiraterone or enzalutamide is a major medical burden — the duration of benefit is highly variable and cross-resistance often occurs when these two agents are given

sequentially. Blood-based analysis of androgen receptor splice variants and _AR_ copy number gain or mutations could enhance understanding of the mechanisms of resistance and improve

management of patients with castration-resistant prostate cancer. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

RELEVANT ARTICLES Open Access articles citing this article. * SEOM CLINICAL GUIDELINES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER (2020) * A. González del Alba * , M. J. Méndez-Vidal *  …

 J. A. Arranz _Clinical and Translational Oncology_ Open Access 24 February 2021 * THE ANDROGEN RECEPTOR/FILAMIN A COMPLEX AS A TARGET IN PROSTATE CANCER MICROENVIRONMENT * Marzia Di Donato

* , Alice Zamagni *  … Gabriella Castoria _Cell Death & Disease_ Open Access 26 January 2021 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES *

Nakazawa, M., Antonarakis, E. S. & Luo, J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. _Horm. Cancer_ 5, 265–273 (2014). Article  CAS  Google Scholar  *

Antonarakis E. S. _ et al_. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. _N. Engl. J. Med._ 371, 1028–1038 (2014). Article  Google Scholar  * Romanel, A. _ et

al_. Plasma _AR_ and abiraterone-resistant prostate cancer. _Sci. Transl Med._ 7, 312re310 (2015). Article  Google Scholar  * Wyatt, A. W. _ et al_. Genomic alterations in cell-free DNA and

enzalutamide resistance in castration-resistant prostate cancer. _JAMA Oncol._ http://dx.doi.org/10.1001/jamaoncol.2016.0494 (2016). * Scher, H. I. _ et al_. Association of AR-V7 on

circulating tumor cells as a tTeatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. _JAMA Oncol._, http://dx.doi.org/10.1001/jamaoncol.2016.1828

(2016). * Antonarakis, E. S. _ et al_. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. _Oncologist_

http://dx.doi.org/10.1634/theoncologist.2016-0161 (2016). * Bernemann, C. _ et al_. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen

deprivation therapy in patients with castration resistant prostate cancer. _Eur. Urol._ http://dx.doi.org/10.1016/j.eururo.2016.07.021 (2016). * Antonarakis, E. _ et al_. AR-V7 and efficacy

of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): expanded analysis of the Johns Hopkins cohort [abstract 5012]. _J. Clin. Oncol._ 34 (Suppl.)

(2016). * Carreira, S. _ et al_. Tumor clone dynamics in lethal prostate cancer. _Sci. Transl Med._ 6, 254ra125 (2014). Article  Google Scholar  * Miyamoto, D. T. _ et al_. RNA-seq of single

prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. _Science_ 349, 1351–1356 (2015). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS

AND AFFILIATIONS * Gerhardt Attard is at the Centre of Evolution and Cancer, The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK; and at The Royal Marsden NHS

Foundation Trust, Fulham Road, London SW3 6JJ, UK., Gerhardt Attard * and at The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK., Gerhardt Attard * Emmanuel S.

Antonarakis is at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 1650 Orleans Street, CRB1–1M45, Baltimore, Maryland 21231, USA., Emmanuel S. Antonarakis Authors * Gerhardt

Attard View author publications You can also search for this author inPubMed Google Scholar * Emmanuel S. Antonarakis View author publications You can also search for this author inPubMed 

Google Scholar CORRESPONDING AUTHORS Correspondence to Gerhardt Attard or Emmanuel S. Antonarakis. ETHICS DECLARATIONS COMPETING INTERESTS G.A. has received honoraria, consulting fees or

travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Bayer, Essa Pharma, Abbott Labs, Novartis, Veridex and Sanofi-Aventis, and grant support from

Janssen, AstraZeneca, Innocrin and Arno. The Institute of Cancer Research (ICR) developed abiraterone and, therefore, has a commercial interest in this agent. G.A. is on the ICR list of

rewards to inventors for abiraterone. E.S.A. has served as a paid consultant and/or adviser for Janssen, Astellas, Essa, and Medivation; has received research funding to his institution from

Janssen, Johnson & Johnson, Medivation, and Tokai; and is a coinventor of a biomarker technology that has been licensed to Tokai. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Attard, G., Antonarakis, E. AR aberrations and resistance to abiraterone or enzalutamide. _Nat Rev Urol_ 13, 697–698 (2016).

https://doi.org/10.1038/nrurol.2016.212 Download citation * Published: 02 November 2016 * Issue Date: December 2016 * DOI: https://doi.org/10.1038/nrurol.2016.212 SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative